| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Infection Control | 8 | 2020 | 105 | 2.290 |
Why?
|
| Cross Infection | 7 | 2019 | 167 | 2.190 |
Why?
|
| Bacteremia | 7 | 2022 | 94 | 2.050 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 5 | 2022 | 66 | 1.890 |
Why?
|
| Staphylococcal Infections | 8 | 2022 | 130 | 1.560 |
Why?
|
| Intensive Care Units | 11 | 2025 | 414 | 1.250 |
Why?
|
| Vancomycin-Resistant Enterococci | 3 | 2018 | 12 | 1.140 |
Why?
|
| Gram-Positive Bacterial Infections | 3 | 2017 | 30 | 1.070 |
Why?
|
| Influenza, Human | 2 | 2025 | 212 | 1.040 |
Why?
|
| Respiratory Tract Infections | 2 | 2025 | 90 | 0.990 |
Why?
|
| Needlestick Injuries | 2 | 2015 | 19 | 0.950 |
Why?
|
| Metapneumovirus | 1 | 2025 | 5 | 0.930 |
Why?
|
| Paramyxoviridae Infections | 1 | 2025 | 7 | 0.930 |
Why?
|
| Blood-Borne Pathogens | 2 | 2015 | 12 | 0.910 |
Why?
|
| Soft Tissue Infections | 2 | 2022 | 49 | 0.830 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2022 | 11 | 0.740 |
Why?
|
| Pneumonia, Ventilator-Associated | 4 | 2015 | 37 | 0.720 |
Why?
|
| Community-Acquired Infections | 1 | 2022 | 94 | 0.690 |
Why?
|
| Disease Outbreaks | 4 | 2020 | 116 | 0.690 |
Why?
|
| Candidemia | 2 | 2018 | 9 | 0.660 |
Why?
|
| Laboratories | 1 | 2020 | 27 | 0.640 |
Why?
|
| Pseudomonas Infections | 3 | 2017 | 54 | 0.620 |
Why?
|
| Fungemia | 1 | 2019 | 6 | 0.620 |
Why?
|
| Molecular Typing | 1 | 2019 | 10 | 0.610 |
Why?
|
| Communicable Diseases | 1 | 2020 | 91 | 0.600 |
Why?
|
| Genome, Bacterial | 1 | 2019 | 68 | 0.590 |
Why?
|
| Lactoferrin | 7 | 1994 | 37 | 0.580 |
Why?
|
| Whole Genome Sequencing | 1 | 2019 | 84 | 0.580 |
Why?
|
| Anti-Bacterial Agents | 6 | 2015 | 800 | 0.540 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2017 | 24 | 0.520 |
Why?
|
| Occupational Exposure | 2 | 2015 | 315 | 0.480 |
Why?
|
| Academic Medical Centers | 4 | 2017 | 313 | 0.460 |
Why?
|
| Accidents, Occupational | 1 | 2015 | 44 | 0.460 |
Why?
|
| Humans | 58 | 2025 | 64272 | 0.440 |
Why?
|
| Pressure Ulcer | 1 | 2014 | 34 | 0.440 |
Why?
|
| Hand Hygiene | 2 | 2015 | 10 | 0.430 |
Why?
|
| Body Fluids | 1 | 2014 | 21 | 0.420 |
Why?
|
| Beds | 1 | 2014 | 10 | 0.420 |
Why?
|
| Ventilator-Induced Lung Injury | 1 | 2013 | 10 | 0.410 |
Why?
|
| Accidental Falls | 1 | 2014 | 125 | 0.400 |
Why?
|
| Housekeeping, Hospital | 1 | 2013 | 4 | 0.400 |
Why?
|
| Disinfection | 1 | 2013 | 22 | 0.390 |
Why?
|
| Guideline Adherence | 2 | 2013 | 306 | 0.390 |
Why?
|
| Practice Guidelines as Topic | 2 | 2013 | 726 | 0.380 |
Why?
|
| Population Surveillance | 1 | 2013 | 209 | 0.380 |
Why?
|
| Environmental Exposure | 1 | 2014 | 220 | 0.370 |
Why?
|
| Critical Illness | 2 | 2015 | 327 | 0.350 |
Why?
|
| Retrospective Studies | 9 | 2025 | 6741 | 0.340 |
Why?
|
| Respiration, Artificial | 1 | 2013 | 296 | 0.340 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2011 | 91 | 0.320 |
Why?
|
| Critical Care | 3 | 2020 | 402 | 0.310 |
Why?
|
| Transferrin | 4 | 1990 | 70 | 0.290 |
Why?
|
| Infant | 4 | 2025 | 1664 | 0.290 |
Why?
|
| Child | 5 | 2025 | 4583 | 0.290 |
Why?
|
| Algorithms | 1 | 2013 | 1029 | 0.280 |
Why?
|
| Child, Preschool | 5 | 2025 | 2019 | 0.280 |
Why?
|
| Male | 26 | 2025 | 30322 | 0.280 |
Why?
|
| Caliciviridae Infections | 1 | 2007 | 5 | 0.270 |
Why?
|
| Norovirus | 1 | 2007 | 7 | 0.270 |
Why?
|
| Gram-Negative Bacteria | 3 | 1994 | 56 | 0.270 |
Why?
|
| Gastroenteritis | 1 | 2007 | 14 | 0.270 |
Why?
|
| Adult | 18 | 2025 | 17136 | 0.270 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2007 | 5 | 0.270 |
Why?
|
| Contact Tracing | 1 | 2007 | 17 | 0.270 |
Why?
|
| Whooping Cough | 1 | 2007 | 10 | 0.270 |
Why?
|
| Massachusetts | 5 | 2019 | 2096 | 0.260 |
Why?
|
| Delivery of Health Care | 1 | 2011 | 437 | 0.250 |
Why?
|
| Complement System Proteins | 4 | 1990 | 105 | 0.250 |
Why?
|
| Adolescent | 7 | 2025 | 6306 | 0.240 |
Why?
|
| Hemorrhagic Fever, Ebola | 2 | 2016 | 29 | 0.240 |
Why?
|
| Pandemics | 1 | 2011 | 676 | 0.240 |
Why?
|
| Ebolavirus | 2 | 2016 | 39 | 0.240 |
Why?
|
| Seasons | 1 | 2025 | 138 | 0.220 |
Why?
|
| Public Health Surveillance | 2 | 2015 | 28 | 0.220 |
Why?
|
| Staphylococcus aureus | 3 | 2022 | 179 | 0.220 |
Why?
|
| Central Venous Catheters | 2 | 2015 | 17 | 0.210 |
Why?
|
| Urinary Tract Infections | 2 | 2017 | 93 | 0.210 |
Why?
|
| Influenza A virus | 1 | 2025 | 124 | 0.210 |
Why?
|
| Lactoglobulins | 3 | 1990 | 52 | 0.210 |
Why?
|
| Catheter-Related Infections | 2 | 2015 | 43 | 0.210 |
Why?
|
| Young Adult | 3 | 2025 | 4782 | 0.200 |
Why?
|
| Pneumonia, Pneumocystis | 2 | 1995 | 19 | 0.200 |
Why?
|
| Middle Aged | 12 | 2025 | 17923 | 0.200 |
Why?
|
| APACHE | 3 | 2017 | 43 | 0.190 |
Why?
|
| Aged | 8 | 2025 | 14663 | 0.190 |
Why?
|
| Aged, 80 and over | 2 | 2025 | 5528 | 0.190 |
Why?
|
| Sex Factors | 1 | 2025 | 980 | 0.190 |
Why?
|
| Leukocidins | 1 | 2022 | 8 | 0.190 |
Why?
|
| Exotoxins | 1 | 2022 | 9 | 0.190 |
Why?
|
| HIV Infections | 4 | 2000 | 976 | 0.190 |
Why?
|
| Fever | 1 | 2022 | 66 | 0.180 |
Why?
|
| Female | 16 | 2025 | 33383 | 0.180 |
Why?
|
| Patient Isolation | 2 | 2014 | 7 | 0.180 |
Why?
|
| Bacterial Toxins | 1 | 2022 | 63 | 0.180 |
Why?
|
| Incidence | 1 | 2025 | 1386 | 0.170 |
Why?
|
| Respiratory Protective Devices | 1 | 2020 | 13 | 0.170 |
Why?
|
| DNA Polymerase III | 1 | 2000 | 28 | 0.160 |
Why?
|
| Microbiology | 1 | 2020 | 6 | 0.160 |
Why?
|
| Gram-Positive Bacteria | 1 | 2000 | 36 | 0.160 |
Why?
|
| Helicobacter pylori | 3 | 1997 | 59 | 0.160 |
Why?
|
| Uracil | 1 | 2000 | 33 | 0.160 |
Why?
|
| Ownership | 1 | 2020 | 19 | 0.160 |
Why?
|
| North America | 1 | 2020 | 112 | 0.160 |
Why?
|
| Helicobacter Infections | 2 | 1997 | 55 | 0.160 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 1997 | 82 | 0.150 |
Why?
|
| Molecular Epidemiology | 1 | 2019 | 32 | 0.150 |
Why?
|
| Case-Control Studies | 1 | 2022 | 1131 | 0.150 |
Why?
|
| United States | 2 | 2025 | 7923 | 0.140 |
Why?
|
| Trimethoprim | 2 | 1991 | 7 | 0.140 |
Why?
|
| Cluster Analysis | 1 | 2019 | 263 | 0.140 |
Why?
|
| Enzyme Inhibitors | 1 | 2000 | 373 | 0.140 |
Why?
|
| Shock, Septic | 1 | 1999 | 85 | 0.140 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2018 | 21 | 0.140 |
Why?
|
| Liver Transplantation | 1 | 2020 | 217 | 0.140 |
Why?
|
| Drug Users | 1 | 2018 | 27 | 0.140 |
Why?
|
| Glucocorticoids | 1 | 1999 | 189 | 0.130 |
Why?
|
| Logistic Models | 3 | 2017 | 1270 | 0.130 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2018 | 80 | 0.130 |
Why?
|
| Blood Culture | 1 | 2017 | 10 | 0.130 |
Why?
|
| Liver Diseases | 2 | 1990 | 160 | 0.130 |
Why?
|
| Hepatitis B Core Antigens | 1 | 1996 | 6 | 0.130 |
Why?
|
| Magnesium | 3 | 1993 | 55 | 0.130 |
Why?
|
| Hepatitis B Antibodies | 1 | 1996 | 9 | 0.130 |
Why?
|
| Gastrointestinal Diseases | 1 | 2017 | 71 | 0.120 |
Why?
|
| Hepatitis B Vaccines | 1 | 1996 | 15 | 0.120 |
Why?
|
| Meningitis | 2 | 1987 | 18 | 0.120 |
Why?
|
| Linear Models | 1 | 2017 | 408 | 0.120 |
Why?
|
| RNA, Viral | 2 | 2000 | 276 | 0.120 |
Why?
|
| Semen | 1 | 2016 | 48 | 0.120 |
Why?
|
| Mortality | 1 | 2017 | 161 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2019 | 1020 | 0.120 |
Why?
|
| Anesthesia, Local | 1 | 2015 | 20 | 0.120 |
Why?
|
| Carrier State | 3 | 2017 | 18 | 0.120 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 122 | 0.120 |
Why?
|
| Police | 1 | 2015 | 39 | 0.120 |
Why?
|
| Hospitals | 2 | 2017 | 390 | 0.120 |
Why?
|
| Uveitis | 1 | 2016 | 34 | 0.110 |
Why?
|
| Sulfadoxine | 1 | 1995 | 15 | 0.110 |
Why?
|
| Pyrimethamine | 1 | 1995 | 20 | 0.110 |
Why?
|
| Patient Admission | 1 | 2017 | 198 | 0.110 |
Why?
|
| Muramidase | 2 | 1993 | 47 | 0.110 |
Why?
|
| Meningococcal Infections | 2 | 1986 | 21 | 0.110 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1995 | 68 | 0.110 |
Why?
|
| HIV-1 | 2 | 2000 | 725 | 0.110 |
Why?
|
| Infant, Newborn | 1 | 2019 | 1375 | 0.110 |
Why?
|
| Emergency Medicine | 1 | 2017 | 193 | 0.110 |
Why?
|
| Catheterization, Central Venous | 1 | 2015 | 83 | 0.110 |
Why?
|
| Calcium | 3 | 1993 | 580 | 0.100 |
Why?
|
| Risk Factors | 5 | 2018 | 5341 | 0.100 |
Why?
|
| Sepsis | 3 | 1986 | 290 | 0.100 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2013 | 34 | 0.100 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2020 | 209 | 0.100 |
Why?
|
| Cefotaxime | 2 | 1990 | 4 | 0.100 |
Why?
|
| Bacteria | 2 | 1993 | 317 | 0.090 |
Why?
|
| Patient Care Team | 1 | 2015 | 340 | 0.090 |
Why?
|
| Cohort Studies | 2 | 2016 | 2605 | 0.090 |
Why?
|
| Sulfamethizole | 1 | 1991 | 2 | 0.090 |
Why?
|
| Rifampin | 3 | 1990 | 25 | 0.090 |
Why?
|
| Agranulocytosis | 1 | 1991 | 6 | 0.090 |
Why?
|
| Enterobacteriaceae Infections | 1 | 1991 | 11 | 0.090 |
Why?
|
| Health Personnel | 1 | 2015 | 389 | 0.090 |
Why?
|
| Peptide Fragments | 1 | 1993 | 417 | 0.080 |
Why?
|
| Lung | 2 | 1986 | 964 | 0.080 |
Why?
|
| Listeria monocytogenes | 1 | 1990 | 34 | 0.080 |
Why?
|
| Hospitals, Veterans | 2 | 1996 | 159 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 1990 | 519 | 0.070 |
Why?
|
| Escherichia coli | 3 | 1990 | 718 | 0.070 |
Why?
|
| Enterobacteriaceae | 1 | 1988 | 18 | 0.070 |
Why?
|
| Quality Improvement | 1 | 2013 | 455 | 0.070 |
Why?
|
| Amino Acid Sequence | 5 | 2015 | 1597 | 0.070 |
Why?
|
| Lipopolysaccharides | 4 | 1993 | 625 | 0.070 |
Why?
|
| Colorado Tick Fever | 1 | 1987 | 1 | 0.070 |
Why?
|
| Reoviridae Infections | 1 | 1987 | 1 | 0.070 |
Why?
|
| Rickettsiaceae Infections | 1 | 1987 | 5 | 0.070 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1988 | 93 | 0.070 |
Why?
|
| Dermatitis, Exfoliative | 1 | 1987 | 3 | 0.070 |
Why?
|
| Pertussis Vaccine | 1 | 2007 | 2 | 0.070 |
Why?
|
| Bordetella pertussis | 1 | 2007 | 9 | 0.070 |
Why?
|
| Coitus | 1 | 1987 | 15 | 0.070 |
Why?
|
| Candidiasis | 1 | 1987 | 51 | 0.070 |
Why?
|
| Microscopy, Electron | 3 | 1993 | 251 | 0.060 |
Why?
|
| Personnel, Hospital | 1 | 2007 | 45 | 0.060 |
Why?
|
| Streptococcal Infections | 1 | 1987 | 80 | 0.060 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1987 | 137 | 0.060 |
Why?
|
| Immunization, Passive | 2 | 1996 | 96 | 0.060 |
Why?
|
| Hospital Costs | 1 | 2007 | 126 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 544 | 0.060 |
Why?
|
| Hemarthrosis | 1 | 1986 | 3 | 0.060 |
Why?
|
| Escherichia coli Infections | 1 | 1986 | 89 | 0.060 |
Why?
|
| Iron | 1 | 1986 | 154 | 0.060 |
Why?
|
| Hemophilia A | 1 | 1986 | 57 | 0.060 |
Why?
|
| Gonorrhea | 1 | 1987 | 160 | 0.060 |
Why?
|
| Arthritis | 1 | 1986 | 53 | 0.060 |
Why?
|
| Aeromonas | 1 | 1984 | 6 | 0.060 |
Why?
|
| Disasters | 1 | 1985 | 29 | 0.050 |
Why?
|
| Sulfamethoxazole | 1 | 1984 | 5 | 0.050 |
Why?
|
| Transportation of Patients | 1 | 1985 | 50 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 1990 | 462 | 0.050 |
Why?
|
| Cattle | 2 | 1994 | 316 | 0.050 |
Why?
|
| Molecular Sequence Data | 4 | 1994 | 1999 | 0.050 |
Why?
|
| Colorado | 4 | 1992 | 21 | 0.050 |
Why?
|
| Time Factors | 5 | 2017 | 3725 | 0.050 |
Why?
|
| Drug Therapy, Combination | 3 | 2000 | 467 | 0.050 |
Why?
|
| Bacterial Proteins | 3 | 2015 | 775 | 0.050 |
Why?
|
| Mediastinal Diseases | 1 | 1981 | 15 | 0.050 |
Why?
|
| Hospitals, University | 2 | 1992 | 56 | 0.040 |
Why?
|
| Water Microbiology | 2 | 1992 | 15 | 0.040 |
Why?
|
| Diagnosis, Differential | 3 | 1991 | 984 | 0.040 |
Why?
|
| Peptides | 1 | 1985 | 590 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2014 | 3318 | 0.040 |
Why?
|
| Equipment Reuse | 1 | 2020 | 4 | 0.040 |
Why?
|
| Enterococcus | 1 | 2000 | 10 | 0.040 |
Why?
|
| Candidiasis, Invasive | 1 | 2020 | 9 | 0.040 |
Why?
|
| Decontamination | 1 | 2020 | 13 | 0.040 |
Why?
|
| Masks | 1 | 2020 | 23 | 0.040 |
Why?
|
| Ventilators, Mechanical | 1 | 2020 | 30 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 1981 | 195 | 0.040 |
Why?
|
| Candida | 1 | 2020 | 41 | 0.040 |
Why?
|
| HIV Long Terminal Repeat | 1 | 2000 | 12 | 0.040 |
Why?
|
| Hemorrhage | 1 | 1981 | 275 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2020 | 128 | 0.040 |
Why?
|
| Cell Membrane | 2 | 1993 | 501 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 1999 | 194 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2000 | 156 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 1996 | 744 | 0.030 |
Why?
|
| Drug Combinations | 2 | 1991 | 168 | 0.030 |
Why?
|
| Neutrophils | 2 | 1994 | 378 | 0.030 |
Why?
|
| Gastritis | 1 | 1997 | 17 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 54 | 0.030 |
Why?
|
| Base Sequence | 2 | 2015 | 1335 | 0.030 |
Why?
|
| Organizational Policy | 1 | 2017 | 52 | 0.030 |
Why?
|
| Epidemiologic Factors | 1 | 1996 | 4 | 0.030 |
Why?
|
| Klebsiella Infections | 1 | 1996 | 22 | 0.030 |
Why?
|
| Hepatitis B | 1 | 1996 | 33 | 0.030 |
Why?
|
| Cross Reactions | 1 | 1996 | 134 | 0.030 |
Why?
|
| Liberia | 1 | 2016 | 11 | 0.030 |
Why?
|
| Hot Temperature | 2 | 1988 | 139 | 0.030 |
Why?
|
| Nafcillin | 1 | 2015 | 2 | 0.030 |
Why?
|
| Penicillin-Binding Proteins | 1 | 2015 | 9 | 0.030 |
Why?
|
| Complement C8 | 2 | 1987 | 2 | 0.030 |
Why?
|
| Frameshift Mutation | 1 | 2015 | 29 | 0.030 |
Why?
|
| Vancomycin | 1 | 2015 | 39 | 0.030 |
Why?
|
| Prosthesis-Related Infections | 1 | 2015 | 35 | 0.030 |
Why?
|
| Pentamidine | 1 | 1995 | 2 | 0.030 |
Why?
|
| Staphylococcus | 1 | 2015 | 17 | 0.030 |
Why?
|
| Zidovudine | 1 | 1995 | 12 | 0.030 |
Why?
|
| Chlorhexidine | 1 | 2015 | 19 | 0.030 |
Why?
|
| Reference Values | 2 | 2000 | 333 | 0.030 |
Why?
|
| Meningitis, Meningococcal | 2 | 1986 | 8 | 0.030 |
Why?
|
| Survivors | 1 | 2016 | 182 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 1119 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 1995 | 158 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 107 | 0.030 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2015 | 166 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2015 | 268 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 1994 | 22 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2015 | 498 | 0.030 |
Why?
|
| Blood Bactericidal Activity | 1 | 1994 | 62 | 0.030 |
Why?
|
| Tomography, Optical Coherence | 1 | 2016 | 227 | 0.030 |
Why?
|
| Animals | 5 | 1994 | 20955 | 0.030 |
Why?
|
| Pepsin A | 1 | 1993 | 7 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1994 | 365 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 1997 | 479 | 0.020 |
Why?
|
| Molecular Weight | 3 | 1991 | 190 | 0.020 |
Why?
|
| Cholera | 1 | 1992 | 14 | 0.020 |
Why?
|
| Sunlight | 1 | 1992 | 30 | 0.020 |
Why?
|
| Dialysis | 1 | 1991 | 8 | 0.020 |
Why?
|
| Patient Safety | 1 | 2014 | 243 | 0.020 |
Why?
|
| Chelating Agents | 1 | 1991 | 51 | 0.020 |
Why?
|
| Campylobacter jejuni | 1 | 1991 | 13 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 1991 | 89 | 0.020 |
Why?
|
| Staphylococcus epidermidis | 1 | 1991 | 10 | 0.020 |
Why?
|
| Hospitals, General | 1 | 1991 | 17 | 0.020 |
Why?
|
| Opportunistic Infections | 1 | 1991 | 30 | 0.020 |
Why?
|
| Culture Media | 1 | 1991 | 79 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2014 | 335 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 2048 | 0.020 |
Why?
|
| Length of Stay | 1 | 2014 | 819 | 0.020 |
Why?
|
| Listeria | 1 | 1990 | 11 | 0.020 |
Why?
|
| Deoxycholic Acid | 1 | 1990 | 7 | 0.020 |
Why?
|
| Polymyxin B | 1 | 1990 | 9 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1990 | 106 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 1991 | 200 | 0.020 |
Why?
|
| Drug Resistance, Microbial | 1 | 1990 | 48 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 1992 | 150 | 0.020 |
Why?
|
| Hypoxia | 1 | 1991 | 116 | 0.020 |
Why?
|
| Prothrombin Time | 1 | 1990 | 6 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 1407 | 0.020 |
Why?
|
| Vibrio Infections | 1 | 1989 | 3 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2014 | 870 | 0.020 |
Why?
|
| Drug Synergism | 1 | 1990 | 142 | 0.020 |
Why?
|
| Species Specificity | 1 | 1990 | 334 | 0.020 |
Why?
|
| Vibrio cholerae | 1 | 1989 | 18 | 0.020 |
Why?
|
| Wound Infection | 1 | 1989 | 29 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 1991 | 230 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 1988 | 39 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2017 | 1118 | 0.020 |
Why?
|
| Campylobacter fetus | 1 | 1988 | 1 | 0.020 |
Why?
|
| Kinetics | 1 | 1990 | 766 | 0.020 |
Why?
|
| Penicillin Resistance | 2 | 1986 | 11 | 0.020 |
Why?
|
| Complement Activating Enzymes | 1 | 1987 | 1 | 0.020 |
Why?
|
| Complement C1r | 1 | 1987 | 1 | 0.020 |
Why?
|
| Hemolytic Plaque Technique | 1 | 1987 | 11 | 0.020 |
Why?
|
| Complement C4 | 1 | 1987 | 12 | 0.020 |
Why?
|
| Ehrlichia | 1 | 1987 | 3 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 1988 | 490 | 0.020 |
Why?
|
| Complement C1 | 1 | 1987 | 3 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 1997 | 458 | 0.020 |
Why?
|
| Lymphatic Diseases | 1 | 1987 | 13 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 1990 | 1164 | 0.020 |
Why?
|
| Perineum | 1 | 1987 | 19 | 0.020 |
Why?
|
| Cell Division | 1 | 1988 | 455 | 0.020 |
Why?
|
| Rabbits | 1 | 1988 | 333 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 1987 | 46 | 0.020 |
Why?
|
| Leg | 1 | 1987 | 87 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 1988 | 212 | 0.020 |
Why?
|
| Streptococcus agalactiae | 1 | 1987 | 79 | 0.020 |
Why?
|
| Mice | 2 | 1994 | 10994 | 0.020 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 1987 | 65 | 0.020 |
Why?
|
| Albumins | 1 | 1986 | 37 | 0.020 |
Why?
|
| Aerosols | 1 | 1986 | 47 | 0.020 |
Why?
|
| Antibodies, Bacterial | 2 | 1997 | 182 | 0.020 |
Why?
|
| Suppuration | 1 | 1986 | 11 | 0.020 |
Why?
|
| Arthritis, Infectious | 1 | 1986 | 20 | 0.020 |
Why?
|
| Edetic Acid | 1 | 1985 | 24 | 0.010 |
Why?
|
| Recurrence | 1 | 1987 | 652 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 1985 | 65 | 0.010 |
Why?
|
| Neisseria meningitidis | 1 | 1986 | 78 | 0.010 |
Why?
|
| Liver | 1 | 1990 | 868 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 1988 | 671 | 0.010 |
Why?
|
| Glucose | 1 | 1988 | 471 | 0.010 |
Why?
|
| Gentamicins | 1 | 1984 | 25 | 0.010 |
Why?
|
| Phosphates | 1 | 1985 | 93 | 0.010 |
Why?
|
| Acute Disease | 1 | 1986 | 671 | 0.010 |
Why?
|
| Methicillin | 1 | 1984 | 5 | 0.010 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1984 | 10 | 0.010 |
Why?
|
| Complement C6 | 1 | 1983 | 2 | 0.010 |
Why?
|
| Pericarditis | 1 | 1983 | 10 | 0.010 |
Why?
|
| Hepatitis, Alcoholic | 1 | 1984 | 78 | 0.010 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1983 | 171 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 1991 | 5696 | 0.010 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2000 | 28 | 0.010 |
Why?
|
| Pregnancy | 1 | 1987 | 2370 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2000 | 93 | 0.010 |
Why?
|
| Radiography | 1 | 1981 | 553 | 0.010 |
Why?
|
| DNA Primers | 1 | 2000 | 295 | 0.010 |
Why?
|
| Amino Acids | 2 | 1991 | 148 | 0.010 |
Why?
|
| Viral Load | 1 | 2000 | 233 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2000 | 203 | 0.010 |
Why?
|
| Virus Replication | 1 | 2000 | 324 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 1983 | 347 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 1997 | 98 | 0.010 |
Why?
|
| ROC Curve | 1 | 1997 | 288 | 0.010 |
Why?
|
| O Antigens | 1 | 1996 | 5 | 0.010 |
Why?
|
| Immunotoxins | 1 | 1996 | 7 | 0.010 |
Why?
|
| Klebsiella | 1 | 1996 | 10 | 0.010 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1996 | 34 | 0.010 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1996 | 46 | 0.010 |
Why?
|
| Pseudomonas aeruginosa | 1 | 1996 | 108 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1997 | 463 | 0.010 |
Why?
|
| South America | 1 | 1992 | 26 | 0.010 |
Why?
|
| Pharmacy and Therapeutics Committee | 1 | 1992 | 2 | 0.010 |
Why?
|
| Campylobacter Infections | 1 | 1991 | 4 | 0.010 |
Why?
|
| Isoelectric Point | 1 | 1991 | 12 | 0.010 |
Why?
|
| Primates | 1 | 1991 | 55 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1991 | 183 | 0.010 |
Why?
|
| Endopeptidases | 1 | 1991 | 68 | 0.010 |
Why?
|
| Diarrhea | 1 | 1991 | 76 | 0.010 |
Why?
|
| Blotting, Western | 1 | 1991 | 614 | 0.010 |
Why?
|
| Fresh Water | 1 | 1989 | 13 | 0.000 |
Why?
|
| Isoelectric Focusing | 1 | 1988 | 12 | 0.000 |
Why?
|
| Sulfadiazine | 1 | 1986 | 2 | 0.000 |
Why?
|
| Penicillins | 1 | 1986 | 30 | 0.000 |
Why?
|
| Injections, Intravenous | 1 | 1986 | 156 | 0.000 |
Why?
|